Ann: 2022 Annual Report & Annual General Meeting Date, page-3

Dear Shareholders,
I am very excited to be expanding my role with the Company.
I’ve been a Non-executive Director for a touch over 2 years now and I’ve had the opportunity to see the business progress and de-risk over this time.
Initial Impressions
What I see is a business with tremendous opportunities in front of it. The Company has a strong management team that has built a great product and platform and I’m excited to get involved and lend my experience to assist in unlocking that
potential and assist in reaching our goals. My focus will be utilising my experience to help obtain
reimbursement. This is the key to accelerating sales. We expect initial acceleration before reimbursement as hospitals open up, but long-term growth will require us to be successful in obtaining reimbursement. The Company is in a sound financial position with enough capital to reach breakeven. But we need to accelerate sales.
Incremental growth through the global health pandemic has
been a fantastic result but now we need to accelerate growth and I believe we are well positioned toachieve that. Reimbursement
Central to our focus on accelerating growth is reimbursement.
Our internal reimbursement team has made great progress and I believe are on track to achieving reimbursement.
The Case Assistance Program numbers are impressive, with
over 3,600 case wins at a rate of 99%, and importantly 300+ external appeal wins.
In my experience it’s not a question of if we get reimbursement, but just a question of when. There is work to
be done, but I have to say I’m very impressed with the appeals
win rate. From my experience, this is a higher win rate than what was required to achieve reimbursement in other verticals of care.
We already have a number of important payor meetings scheduled this quarter, and I will be looking to utilise my experience and contacts to ensure we have everything we
need to be successful in that process.
Additionally, the NCCN submissions provide us a dual track process to reimbursement. Both paths lead to the same outcome – reimbursement. Most companies only have the traditional path available to them. We are fortunate to have the NCCN pathway also potentially available to us. A positive result with the NCCN submissions would be a fantastic outcome, as it would accelerate private payor reimbursement.
While it is definitely no certainty, we believe we have compelling submissions. We would expect to know the outcome before the end of the calendar year.